Trial Profile
A Phase 1 Multicenter Study Evaluating the Safety and Potential Activity Of Three Escalating Doses of hMaxi-K Gene Transfer In Female Participants With Overactive Bladder Syndrome and Detrusor Overactivity: Double Blind, Imbalanced Placebo Controlled Design Within 3 Sequential Active Treatment Groups
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Feb 2020
Price :
$35
*
At a glance
- Drugs Maxi-K gene therapy (Primary)
- Indications Overactive bladder
- Focus Adverse reactions
- Acronyms ION-2
- Sponsors Urovant Sciences
- 04 Feb 2020 According to an Urovant Sciences Media Release, data were published online in Neurology and Urodynamics and Dr. Eric Rovner is the lead author.
- 04 Feb 2020 Results presented in an Urovant Sciences Media Release.
- 26 Jun 2019 Status changed to discontinued.